NASDAQ:RCM - R1 RCM Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $28.57
Forecasted Upside: 37.23 %
Number of Analysts: 7
Breakdown:
0 Sell Ratings
0 Hold Ratings
7 Buy Ratings
0 Strong Buy Ratings

^$20.82 As of 07/23/2021 01:00 AM ET

▲ +0.2 (0.97%)

1 month | 3 months | 12 months

Get New R1 RCM Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for RCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RCM

^$28.57

▲ +37.23% Upside Potential

This price target is based on 7 analysts offering 12 month price targets for R1 RCM in the last 3 months. The average price target is $28.57, with a high forecast of $35.00 and a low forecast of $22.00. The average price target represents a 37.23% upside from the last price of $20.82.

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in R1 RCM. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/31/2020

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/30/2020

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/29/2020

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/27/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/25/2021

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/25/2021

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/24/2021

0 strong buy ratings
7 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/24/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
7/22/2021	Bank of America	Initiated Coverage	Buy	$27.00	Low
6/2/2021	Robert W. Baird	Initiated Coverage	Outperform	$30.00	Medium
5/27/2021	SVB Leerink	Reiterated Rating	Buy		High
2/16/2021	KeyCorp	Boost Price Target		$27.00 ➝ $35.00	Low
2/9/2021	Cowen	Boost Price Target	Outperform	$22.00 ➝ $33.00	Low
1/6/2021	KeyCorp	Boost Price Target	Overweight	$24.00 ➝ $26.00	N/A
12/9/2020	Royal Bank of Canada	Boost Price Target	Outperform	$20.00 ➝ $27.00	Low
12/3/2020	SVB Leerink	Boost Price Target	Outperform	$22.00 ➝ $26.00	Medium
11/4/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$18.00 ➝ $22.00	Medium
11/4/2020	SVB Leerink	Boost Price Target	Outperform	$18.00 ➝ $22.00	Medium
11/2/2020	KeyCorp	Boost Price Target	Overweight	$17.00 ➝ $24.00	High
8/5/2020	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$14.00 ➝ $18.00	Medium
7/14/2020	KeyCorp	Boost Price Target	Overweight	$12.00 ➝ $15.00	Medium
4/20/2020	Royal Bank of Canada	Initiated Coverage	Outperform	$12.00	High
4/13/2020	SVB Leerink	Initiated Coverage	Market Perform	$10.00	Medium
1/21/2020	Cantor Fitzgerald	Reiterated Rating	Overweight	$15.00 ➝ $17.00	High
1/14/2020	KeyCorp	Boost Price Target	Overweight	$14.00 ➝ $15.00	Low
1/10/2020	Dougherty & Co	Initiated Coverage	Buy	$15.00	Medium
9/12/2019	Robert W. Baird	Set Price Target	Buy	$14.00	Low
4/12/2019	Cantor Fitzgerald	Boost Price Target	Overweight	$11.00 ➝ $13.00	Medium
1/22/2019	KeyCorp	Initiated Coverage	Overweight ➝ Overweight	$10.00	High
12/10/2018	Citigroup	Initiated Coverage	Buy ➝ Buy	$20.00	Medium
9/4/2018	Chardan Capital	Initiated Coverage	Buy ➝ Buy	$17.00	High
8/10/2018	Cantor Fitzgerald	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $11.00	Low
7/27/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$10.00	Low
4/9/2018	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$9.00	Medium
3/13/2018	Cantor Fitzgerald	Initiated Coverage	Overweight	$9.00	Medium
3/12/2018	Cowen	Reiterated Rating	Outperform ➝ In-Line	$5.00 ➝ $10.00	Medium
2/26/2018	Robert W. Baird	Reiterated Rating	Hold	$7.00	High
9/26/2017	Robert W. Baird	Reiterated Rating	Hold	$5.00	High
8/24/2017	Robert W. Baird	Reiterated Rating	Hold	$5.00	Low

(Data available from 7/25/2016 forward)

R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Chicago, IL.

Today's Range

Now: $20.82

$20.36

$20.87

50 Day Range

MA: $22.36

$19.88

$25.41

52 Week Range

Now: $20.82

$13.21

$31.28

Volume

445,973 shs

Average Volume

1,009,934 shs

Market Capitalization

$5.45 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Frequently Asked Questions

What sell-side analysts currently cover shares of R1 RCM?

The following sell-side analysts have issued stock ratings on R1 RCM in the last twelve months: Bank of America Co., Cantor Fitzgerald, Cowen Inc, KeyCorp, Robert W. Baird, Royal Bank of Canada, SVB Leerink LLC, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for RCM.

What is the current price target for R1 RCM?

7 Wall Street analysts have set twelve-month price targets for R1 RCM in the last year. Their average twelve-month price target is $28.57, suggesting a possible upside of 37.2%. KeyCorp has the highest price target set, predicting RCM will reach $35.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $22.00 for R1 RCM in the next year.
View the latest price targets for RCM.

What is the current consensus analyst rating for R1 RCM?

R1 RCM currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RCM will outperform the market and that investors should add to their positions of R1 RCM.
View the latest ratings for RCM.

What other companies compete with R1 RCM?

Other companies that are similar to R1 RCM include Laboratory Co. of America, Quest Diagnostics, DaVita, Amedisys, Chemed, LHC Group, AMN Healthcare Services, MEDNAX, CorVel, Tivity Health and Cross Country Healthcare.

How do I contact R1 RCM's investor relations team?

R1 RCM's physical mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The healthcare provider's listed phone number is (312) 324-7820 and its investor relations email address is [email protected] The official website for R1 RCM is www.r1rcm.com.